Smithbridge Asset Management Inc. DE Purchases Shares of 88,531 Novo Nordisk A/S (NYSE:NVO)

Smithbridge Asset Management Inc. DE bought a new position in Novo Nordisk A/S (NYSE:NVO - Free Report) in the 1st quarter, according to its most recent disclosure with the SEC. The firm bought 88,531 shares of the company's stock, valued at approximately $6,148,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Center for Financial Planning Inc. lifted its position in shares of Novo Nordisk A/S by 72.4% in the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock worth $25,000 after purchasing an additional 123 shares during the period. Strategic Investment Solutions Inc. IL lifted its position in shares of Novo Nordisk A/S by 2,727.3% in the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock worth $27,000 after purchasing an additional 300 shares during the period. Park Square Financial Group LLC purchased a new stake in shares of Novo Nordisk A/S in the 4th quarter worth about $29,000. Transce3nd LLC purchased a new stake in shares of Novo Nordisk A/S in the 4th quarter worth about $33,000. Finally, CX Institutional purchased a new stake in shares of Novo Nordisk A/S in the 1st quarter worth about $36,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Down 1.4%

NYSE:NVO traded down $1.15 on Friday, reaching $79.90. 7,465,072 shares of the stock traded hands, compared to its average volume of 7,025,617. The company has a market capitalization of $358.57 billion, a price-to-earnings ratio of 24.29, a PEG ratio of 0.90 and a beta of 0.66. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. Novo Nordisk A/S has a 12 month low of $57.00 and a 12 month high of $148.15. The company's fifty day simple moving average is $66.93 and its 200 day simple moving average is $80.00.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.92. The firm had revenue of $11.87 billion for the quarter. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Equities analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently issued reports on NVO. Wall Street Zen lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Friday, June 6th. Dbs Bank lowered shares of Novo Nordisk A/S to a "sell" rating in a research note on Friday, April 25th. Hsbc Global Res upgraded shares of Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, April 28th. Stifel Nicolaus lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Finally, BMO Capital Markets reiterated a "market perform" rating and issued a $64.00 price target (down from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $112.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.